reports
- Eivind Sars Veddeng
- Frank Maaø
- Håkon Astrup
- Helge André Martinsen
- Karl-Johan Bonnevier
- Niclas Gehin
- Nicolay Dyvik
- Ole Martin Westgaard
- Ole-Andreas Krohn
- Rune Majlund Dahl
- Simen Mortensen
- Rune Majlund Dahl
- Rune Majlund Dahl
- Antti Kansanen
- Christer Magnergård
- Martin Arnell
- Mattias Holmberg
- Mattias Montgomery
- Niclas Gehin
- Ole-Andreas Krohn
- Patrik Ling
- Rune Majlund Dahl
- Simen Mortensen
- Rune Majlund Dahl
Coloplast (Buy, TP: DKK590.00) - We expect Q2 in line with guidance
Our Q2 organic revenue growth forecast of 7.4% is in line with the c7% full-year guidance (results due around noon on 3 May). We expect continued strong growth in Ostomy and Urology, and improved growth in Wound care QOQ but the division to remain a drag. With increased investments concluded in Q1, we expect the EBIT margin to improve QOQ. We reiterate our BUY and DKK590 target price.
- Alexander Aukner
- Jon Masdal
- Karl-Johan Bonnevier
- Martin Huseby Karlsen
- Niclas Gehin
- Nicolay Dyvik
- Ole-Andreas Krohn
- Paul Harper
- Rune Majlund Dahl
- Tone Bjørnstad Hanstad
- Rune Majlund Dahl
Coloplast (Buy, TP: DKK590.00) - Growth likely to accelerate in 2019
At the time of its strategy update in November Coloplast said it had decided to increase investments with the aim of growing organically at the higher end of its 7–9% long-term target, with the main question for investors being when this will materialise. We still view Coloplast’s history of outgrowing the market a result of its superior product innovation, a trend we expect to accelerate in 2019 on product launches such as SenSura Mio Concave. We see a particularly good buying opportunity a...
- Christer Magnergård
- Frank Maaø
- Håkon Astrup
- Helge André Martinsen
- Jesper Ingildsen
- Karl-Johan Bonnevier
- Mattias Montgomery
- Nicolay Dyvik
- Ole Martin Westgaard
- Ole-Andreas Krohn
- Olof Larshammar
- Paul Harper
- Rune Majlund Dahl
- Simen Mortensen
- Rune Majlund Dahl
- Rune Majlund Dahl
- Rune Majlund Dahl
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.